Hong Kong · Delayed Price · Currency is HKD | Market Cap | 30.03B |
| Revenue (ttm) | 14.64B |
| Net Income (ttm) | 2.83B |
| Shares Out | 1.97B |
| EPS (ttm) | 1.56 |
| PE Ratio | 9.77 |
| Forward PE | 7.37 |
| Dividend | 0.61 (4.02%) |
| Ex-Dividend Date | Jul 8, 2025 |
| Volume | 17,764,921 |
| Average Volume | 22,841,092 |
| Open | 15.48 |
| Previous Close | 15.22 |
| Day's Range | 14.93 - 15.87 |
| 52-Week Range | 8.20 - 17.90 |
| Beta | 0.12 |
| RSI | 49.77 |
| Earnings Date | Aug 29, 2025 |
About Paramount Global
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin... [Read more]
Financial Performance
In 2024, HKG:3933's revenue was 13.76 billion, an increase of 0.14% compared to the previous year's 13.74 billion. Earnings were 2.66 billion, a decrease of -1.54%.
Financial StatementsNews
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2197227495-5a7f9dd0130342a2a3e054c80699c746.jpg)
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.